news
Dual Immune Checkpoint Inhibition with Cemiplimab and Fianlimab Enhances Neoadjuvant Chemotherapy Response in Early-Stage High-Risk ERBB2-Negative Breast Cancer: Insights from the I-SPY2 Trial
The I-SPY2 trial shows that combining PD-1 and LAG-3 inhibitors with neoadjuvant chemotherapy significantly improves pathologic complete response rates in early-stage high-risk ERBB2-negative breast cancer, especially in patients with a pos
